Nuvectis Pharma, Inc.
NVCT
$9.44
-$0.05-0.53%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 14.65% | 13.25% | 5.50% | -10.85% | -16.64% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.25% | 24.45% | 44.74% | 55.74% | 175.63% |
| Change in Net Operating Assets | 18.36% | -70.70% | -19.56% | 13.65% | -58.08% |
| Cash from Operations | 23.24% | 12.73% | 13.86% | -1.80% | -17.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -26.97% | -42.34% | -71.58% | 24.41% | -48.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 72.60% | 84.30% | 74.75% | 56.91% | 65.74% |
| Cash from Financing | -22.75% | -37.73% | -71.30% | 39.16% | -45.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 31.60% | -209.30% | -158.80% | 426.20% | -106.08% |
